Five recommendations on Covid vaccines, and the one the government has not answered yet
What happened
On 16 October 2026, the UK government published its response to Module 4 of the UK Covid-19 Inquiry. Module 4 is the part of the inquiry that looked at vaccines and therapeutics. Therapeutics means the medicines used to treat people who were already ill. The response is a policy paper from the Department of Health and Social Care and the Cabinet Office. The inquiry itself is chaired by Baroness Heather Hallett, and its Module 4 report came out on 16 April 2026. So this is the government answering, six months on. The Module 4 report made five recommendations. Here is what the government has said about each. One: set up an expert advisory panel on pharmaceuticals. The government has agreed to something close to this, but not quite the same thing. It will create an industry stakeholder advisory group with a set advisory role, rather than the standing panel with a wider taskforce job that the inquiry described. Two: build community networks to improve vaccine equity, and report on progress each year. The government agrees with the aim. It will not publish a single annual report. It says it will fit progress reporting into routes that already exist. Three: improve how vaccine uptake is monitored and evaluated. The government has agreed. It says it will line up how public attitude data is collected across all four UK nations, and share that information between them. Four: link healthcare records so vaccine safety can be monitored properly. The government agrees in principle. It says building a UK-wide framework will need more work, proper safeguards, and what it calls likely significant investment. Five: reform the Vaccine Damage Payment Scheme. The government accepts that reform is needed. It has not said what the reform will be. In the ministerial foreword, the Secretary of State for Health and Social Care says the report recognises the success of the vaccines and therapeutics programmes, and adds: "We recognise there is more to do.
Why this matters
Most of this response is about systems. One part of it is about people. The Vaccine Damage Payment Scheme is for the very small number of people who were seriously harmed by a vaccine. It pays a single, fixed, one-off sum of £120,000 to someone found to be at least 60% disabled as a result. There is no sliding scale below that threshold. The inquiry was blunt about it. It described the scheme as not sufficiently supportive and said it needed urgent reform. The government's answer is that it will review the scheme to make sure it is fit for purpose and properly delivered, and that it will work with vaccine-injured people and their families on how it could be strengthened. It has not committed to raising the £120,000 figure. It has not committed to linking the payment to inflation. It has not committed to tiered payments for people who fall below the 60% threshold, or to transitional arrangements. It says further detail will come "in due course". That is the gap worth noticing. On four recommendations, the government has said what it will do. On the fifth, which is the one that affects individual families directly, it has said only that something will be done. The second thing worth noticing is the equity finding. The inquiry found that vaccine uptake was lower in more deprived areas and in some ethnic minority communities, and it called those gaps predictable. Predictable matters, because a predictable gap is one you can plan for in advance rather than discover afterwards.
What the evidence actually says
The inquiry's central safety finding deserves to be stated clearly, because it is often repeated inaccurately in both directions. Module 4 found that the steps taken by the UK government and the regulators to speed up vaccine approval did not compromise the UK's rigorous safety standards. The speed came from doing things in parallel and from working around the clock, not from skipping safety checks. That is the inquiry's own conclusion, reached after hearing evidence over months. That finding sits alongside the recognition that a small number of people were seriously harmed. Both are true at the same time. A vaccine programme can be properly regulated, hugely beneficial overall, and still harm a few individuals badly. Accepting the second does not undo the first. On recommendation four, the linked records point, it is worth understanding what is actually being proposed. Safety monitoring works better when you can see what happened to people after they were vaccinated, across the whole population, rather than relying on individual reports. That needs joined-up health records. The government says it agrees in principle but that the framework does not exist yet, needs safeguards, and will cost real money. That is a realistic answer rather than an enthusiastic one. And on recommendation two, the government is doing something that is easy to miss: it agrees with the goal but is declining the specific mechanism. Refusing to publish one annual report is not the same as refusing to improve vaccine equity, but it does make progress harder for the public to check.
Practical advice
If you think you or a family member were seriously harmed by a vaccine, you can apply to the Vaccine Damage Payment Scheme. Applications are handled by the NHS Business Services Authority, and the details are on GOV.UK. You do not need a solicitor to apply. The scheme is currently unchanged, so do not wait for the reform before applying. If you are unsure whether a health problem is linked to a vaccine, speak to your GP. Getting it recorded in your medical notes matters, both for your own care and because those records are part of how safety signals are spotted. Suspected side effects from any vaccine or medicine can be reported through the MHRA's Yellow Card scheme. Patients and carers can report directly, not just doctors. These reports are one of the main ways problems are detected. If you are deciding about a vaccine now, this inquiry response is not the right document to base that on. It is about how the pandemic programme was run. For a decision about a vaccine today, the useful conversation is with your GP, practice nurse or pharmacist, who can weigh it against your own health. And if you want to follow what happens next, the government has said it will give further details through its inquiry implementation updates. Those are published on GOV.UK.
What to know
The government published its response to Covid-19 Inquiry Module 4 on 16 October 2026. Module 4 covered vaccines and therapeutics and reported on 16 April 2026. There were five recommendations. The government has agreed to the monitoring one, agreed in principle to the linked-records one, agreed to a modified version of the advisory panel, agreed with the aim but not the mechanism on vaccine equity reporting, and accepted that the Vaccine Damage Payment Scheme needs reform without yet saying what that reform is. The inquiry found that the speed of the UK's vaccine approvals did not compromise safety standards. It also found that uptake was lower in deprived areas and some ethnic minority communities, and called that predictable. The Vaccine Damage Payment Scheme is still a one-off £120,000 payment with a 60% disability threshold, and it is still open to applications. Sources: GOV.UK (Department of Health and Social Care and Cabinet Office), "UK government response to the Covid-19 Inquiry Module 4 report", 16 October 2026, https://www.gov.uk/government/publications/uk-government-response-to-the-covid-19-inquiry-module-4-report ; GOV.UK, "UK Covid-19 Inquiry" collection, 16 October 2026, https://www.gov.uk/government/collections/uk-covid-19-inquiry ; UK Covid-19 Inquiry, "Module 4 report: Vaccines and therapeutics", 16 April 2026, https://covid19.public-inquiry.uk/reports/module-4-full-report/ This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. It is not legal advice about making a claim.
Related articles
44% of over-75s are active, against 64% of 55 to 74s: the government replies
On 22 October 2026 the government published its formal reply to a report by the House of Commons Health and Social Care Committee. The committee's report is ca…
£9.4 million to move mental health workers into children's social care teams
On 23 October 2026 the government announced a new mental health pilot for children and young people who are supported by children's social care. The pilot is c…
One tablet a day: the UK has licensed a new psoriasis treatment
On 23 October 2026 the Medicines and Healthcare products Regulatory Agency (MHRA) licensed a new medicine for plaque psoriasis. The medicine is called icotroki…